We analyzed immunohistdemidy the expression of RAR proteins in basal cell carcinomas (BCCs; n = 15) in situ.
Introduction
Retinoic acid (RA) and its metabolites are of great importance for the embryologic development of many vertebrate tissues, including the skin (Lohnes et al., 1995; Hofman and Eichele, 1994; Summerbell and Maden, 1990) . In many different cell types, via binding to corresponding nuclear hormone receptors (retinoic acid receptor-a, -p, -y), RA modulates diverse biological functions such as cell proliferation and cell differentiation and acts on the immune system (Gudas et al., 1994; Peck and DiGiovanna, 1994; Ross and Hhmerling, 1994) . RARs belong to the superfamily of nuclear transcription factors, which includes receptors for all described active steroid hormones, including retinoic acid, 1,25-dihydroxyvitamin D3, and thyroid hormone (Evans, 1988; Green and Chambon, 1988) . Three types of RARs have been identified (RAR-a, $, -y), each encoded by a different gene and occurring in multiple isoforms . They are the ligands for a large number of natural and synthetic metabolites of bcarotene and vitamin A, including all-trans retinoic acid, isotretinoin (13-cis retinoic acid), 942s retinoic acid, etretin, and fenretinide (N(4-hydroxy-Supported in part by the Deutsche Forschungsgemeinschaft (grant * Correspondence tO: Dr. med. Jorg Reichrath, Universitats-Hautklinik, Re 1005/2-1). 66421 HamburgISaar, Germany. phenyl)-retinamide) (Allenby et al., 1994; Moon et al., 1994) . Efficient transcriptional function and DNA binding of RARs to respective retinoic acid response elements (RAREs) in their promoter regions of target genes requires the formation of dimeric complexes. The most potent dimerization partners of RARs known are the retinoid-X receptors (RXRs) (Kliewer et al., 1992; Leid et al., 1992; Zhang et al., 1992) , which are strongly expressed in human skin (Reichrath et al., 1995; Fisher et al., 1994) .
In human skin, RA is believed to play a key role in the regulation of keratinocyte proliferation and differentiation. Keratinocytes grown in vitro show an increased growth rate in the presence of low concentrations of retinoids, whereas high concentrations inhibit keratinocyte proliferation (Kopan et al., 1987; Fuchs and Green, 1981) . In addition, keratinocytes grown under retinoiddepleted conditions express biochemical markers that are associated with terminal differentiation, including keratins 1,10, and 11. Keratinocytes grown in the presence of retinoids express markers typically found in the basal layers of the epidermis (i.e., keratins 13 and 19), indicating a suppressive effect of retinoids on the terminal differentiation of keratinocytes (Fuchs and Green, 1981) .
The induction of RARs has been shown in RA-mediated normal differentiation of rabbit tracheoepithelial cells (Jetten et al., 1987) and in RA-mediated terminal differentiation of embryonic carcinoma cell lines (Hu and Gudas, 1990) . In embryonal carcinoma cell lines, the expression of mutated RAR proteins prevents RA-mediated differentiation (Kruyt et al., 1992; Pratt et al., 1990) . In various human tissues, loss of RAR expression has been associated with acquisition of the malignant phenotype. Malignant tissues obtained from patients with a variety of tumors, including lung carcinoma, squamous cell carcinoma of the head and neck, and breast cancer do not exhibit RAR-0 expression (Swisshelm et al., 1994; Zhang et al., 1994; Hu et ai., 1991) . It has been suggested that RAR-fl may act as a suppressor gene of tumorigenesis in various cell types, including epidermoid lung cells (Houle et al., 1993) . In addition, it was demonstrated that RAR-B inhibits breast carcinoma anchorage-independent growth (Li et al., 1995) . These and other observations support the hypothesis that alterations in function or expression of RARs may be of importance for tumorigenesis of basal cell carcinomas (BCCs).
Isotretinoin was reported previously to be effective in the chemoprevention and chemotherapy of BCCs in patients with multiple BCG (Majewski et al., 1994; Peck et al., 1988 Peck et al., ,1992 Peck, 1987) , but recently chemoprevention of BCCs by retinoids was questioned (Robinson and Salasche, 1992) . Basal cell carcinoma is the most common malignant tumor of the skin (reviewed in Miller, 1991a) . Most theories propose that BCCs arise from keratinocyte stem cells in the epidermal basal layer or from adnexal structures, but consensus concerning the origin and differentiation of this tumor is still lacking. BCCs are semi-malignant skin tumors that are characterized by a locally aggressive and invasive growth pattern but, except for very rare cases, nonmetastasizing behavior (reviewed in Miller, 1991a) . The biological mechanisms underlying these unique characteristics of tumor growth are completely unknown (reviewed in Miller, 1991b) .
The aim of the present study was to investigate RAR protein expression in BCCs of human skin in situ. We addressed the following questions. Which types of RAR-a, -0, -y proteins can be detected immunohistochemically in BCCs in situ? Can we characterize the staining pattern of the different RAR types in human BCCs, and can we correlate expression of RARs with expression of the proliferation marker Ki-67?
Materials and Methods
Skin Specimens. Freshly excised BCC specimens (n = 15) were immediately embedded in OCT-Tissue-Tek I1 (Miles Scientific; Naperville, IL) snap-frozen in liquid nitrogen, and stored at -80°C. The specimens included six BCCs of the nodular type, seven of the superficial type, and two of the fibrosing type.
Primary Antibodies. The different RAR types were detected by the following antibodies, whose preparation and specificity was described previously (Rochette-Egly et a., Gaub et al., 1992 Gaub et al., ,1989 ). These monoclonal antibodies (MAbs) are specific for each of the three types of retinoic acid receptors but do not discriminate between their different isoforms: mouse MAb 9a-9A6 directed against RAR-a (F region); mouse MAb 8p-10B2 directed against RAR-B (F region); and mouse MAb 4y-7A11.1.1.2 directed against RAR-y (F region). A polyclonal rabbit antibody directed against the Ki-67 antigen (Dako A 047; Hamburg, Germany) was used to immunophenotype proliferating cells in BCCs.
Preparation of Sections and Fixation. Serial sections (7 pm) were cut on a cryostat (Reichert-Jung; Heidelberg, Germany) and mounted on pretreated glass slides. Pretreatment of slides with 2 % aminopropylmethoxysilane (Sigma; Miinchen, Getmany) in acetone for 5 min was performed to enhance sticking of sections during the staining procedure. Sections to be stained for RARs were fixed in 3.7% paraformaldehyde (Merck 4005; Darmstadt, Germany) in PBS [lo min at room temperature (RT)], incubated in methanol (Merck 6009; 3 min, -20°C) and acetone (Merck 22; 1 min, -2O'C), and transferred into PBS. Sections to be stained for Ki-67 were air dried (2 hr, RT), followed by fixation in acetone (10 min, RT), air-drying (a few minutes), chloroform (10 min, RT), air-drying, and rinsing in 0.19 M Tris-buffered saline (TBS), pH 7.6 (10 min, RT).
In Situ Detection of RAR Proteins and Ki-67 Antigen. Incubation steps were performed in a moist chamber at RT, covering the sections with 100 p1 of the respective reagents. The slides were incubated with the different RAR antibodies (16 hr, 4°C) at a dilution of 1:lOOO. The Ki-67 antibody was used at a dilution of 1:200 (30 min, RT). After intermediate washing steps (PBSITBS, twice for 5 min). the sections were incubated with biotinlabeled rabbit anti-mouse IgG or goat anti-rabbit IgG (Dako) at a dilution of 1:400 (30 min, RT). and then with streptavidin-peroxidase complexes (Dako) at a dilution of 1:400 (30 min, RT). After rinsing, the sections were incubated with 3-amino-9-ethylcarbazole (AEC; Sigma A 5754) as a substrate for the peroxidase reaction, transferred into tapwater, and mounted with AquaTex (Merck).
In control sections, primary antibodies were replaced with polyclonal mouse IgGl (Dako) or polyclonal rabbit IgGl (Dako). For additional controls, primary RAR antibodies were depleted with the corresponding synthetic peptides (SPB6S for MAb 9a-9A6, SPB66 for MAb 8b-10B2, sP25 for MAb 4y-7.411; a gift from Prof. Chambon) as described previously (Rochette-Egly et al., 1991) . No immunoreactivity was observed when primary antibodies were replaced with polyclonal IgGl or were immunoabsorbed with corresponding peptides.
Results

Expression of RAR-a in Basal Cell Carcinomas
All BCCs analyzed revealed strong nuclear immunoreactivity for RAR-a ( Figures 1A and 1B ). There was no visible difference in comparing the staining patterns for RAR-a in different types of BCCs [nodular type (n = 6), superficial type (n = 7), fibrosing type (n = 2)]. In general, nuclear RAR-a immunoreactivity was pronounced in palisade cells compared to central areas of BCCs. Cells in palisaded array revealed consistently homogeneous and very strong immunoreactivity for RAR-a, whereas staining in central tumor areas was heterogeneous, with visible differences in staining intensity of the RAR-a-positive cells (Figures 1A and 1B) . In addition, staining for RAR-a was stronger in BCCs compared to keratinocytes of uninvolved adjacent epidermis ( Figure IA ; Table 1 ) and compared to hair follicle keratinocytes (data not shown).
Expression of RAR-p in Basal Cell Carcinomas
There was no positive staining reaction for RAR-0 in 12 of 15 BCCs analyzed ( Figure 1C ; Gble 1). Three BCCs revealed very weak nuclear immunoreactivity for RAR-P in single scattered tumor cells ( Figure ID) .
Expression of RAR-y in Basal Cell Carcinomas
All different types of BCCs analyzed revealed nuclear immunoreactivity for RAR-y ( Figures 1E and IF) . Comparing the staining of RAR-a with RAR-y, RAR-y was less intense (Figures lA, lB, and IF). The RAR-y staining pattern was comparable to that of RAR-a, with pronounced nuclear immunoreactivity in palisade and peripheral cells, whereas central tumor areas were labeled less intensely and heterogeneously (Figures lA, lB, 1E, and IF) .
In the epidermal appendages, staining of RAR-a and RAR-y was consistently strong or moderate in hair follicle keratinocytes and cells of sebaceous glands, whereas the MAb directed against RAR-P revealed no or very weak immunoreactivity (data not shown).
In the dermal compartment, the connective tissue gave negative staining results for all different types of RARs. Scattered dermal fibroblasts and endothelial cells appeared to be mostly positive for RAR-a and RAR-y and negative for RAR-P. A large proportion of the mononuclear dermal inflammatory cells was RAR-a-and RARy-positive, whereas only a few scattered dermal mononuclear cells revealed immunoreactivity for RAR-P ( Figures 1A-1F ).
Expression of Ki-67 Antigen in Basal Cell Carcinomas
All BCCs analyzed revealed nuclear immunoreactivity for Ki-67. Whereas in specimens of four tumors the nuclear labeling for Ki-67 was pronounced in peripheral areas and palisade cells ( Figure  1H ), specimens of 11 tumors revealed heterogeneous Ki-67 immunoreactivity with no visible differences between central and peripheral areas ( Figure 1G ).
Discussion
We have immunohistochemically characterized for the first time expression of RAR-a, RAR-P, and RAR-y proteins in BCCs of human skin in situ. Expression of retinoic acid receptor and retinoid-X receptor proteins was analyzed recently in normal human skin (Fisher et al., 1994) , using the same antibodies but different techniques (immunoprecipitation, Western analysis). In that study, almost 90% of RAR protein was represented by RAR-y, the remaining 10% was RAR-a. No RAR-P protein was detected (Fisher et a]., 1994).
Comparing the immunoreactivity of these antibodies directed against the different types of RARs, we found in all types of BCCs (superficial, nodular, fibrosing) strongest staining of RAR-a. The staining intensity of RAR-y was weaker, and the MAb directed against RAR-fi revealed no or very weak immunoreactivity in BCCs. However, it should be noted that analysis of sections stained by different antibodies does not allow a quantitative comparison of the concentrations of the corresponding proteins against which these antibodies are directed.
Our finding of RAR-y protein expression in BCCs reflect results on the mRNA level that were previously published (Finzi et al., 1992) . In that study, expression of RAR-yl mRNA in BCCs was slightly greater than or equal to that in normal epidermis.
Our results demonstrate that the same types of RAR proteins can be detected in BCCs and epidermis of unaffected human skin. Both epidermal keratinocytes and BCCs express RAR-a and RAR-y proteins, whereas RAR-P was hardly detectable. Interestingly, labeling of RAR-a was consistently stronger in all tumor specimens analyzed compared to adjacent epidermis of uninvolved skin, indicating upregulation of RAR-a proteins in BCCs in vivo that may be of importance for the growth of BCCs.
RARs have been shown to act antagonistically to AP-1-mediated activity (Schule et al., 1991) . This antagonism was shown to play a key role in the regulation of collagenase and stromelysin genes, which are important for remodeling of the intercelhlar matrix (Yang-Yen et al., 1991; Nicholson et al., 1990) . This and other unknown mechanisms may be of importance for growth and invasiveness of BCCs. Recently, the induction of apoptosis was implicated in the slow growth of BCCs despite rather high proliferative activity (Mooney et al., 1995) . The RAR-@-selective retinoid R040-6055 is a potent inducer of tissue transglutaminase I1 (TGase 11) and apoptosis in the rat epithelial cell line SPOC-1, whereas RAR-y-selective retinoids are inactive (Zhang et al., 1995) . Because RAR-P is not expressed in SPOC-1 cells, these data suggest that the induction of E a s e I1 expression and apoptosis is mediated via RAR-a signaling pathways. In addition, RARs were shown to upregulate the expression of cytokeratins 13 and 19 which, unlike in normal epidermis, are expressed in BCCs and squamous cell carcinomas (Wu and Rheinwald, 1981) .
It has been speculated that expression of these keratins in squamous cell carcinomas is due to an increased sensitivity for retinoids (Kim et al., 1984) . We demonstrate expression of Ki-67 in BCCs that is comparable to results published recently (Baum et al., 1993) . By analyzing sequential sections of BCCs in situ, only four of 15 tumor specimens revealed visible correlation when we compared expression of RAR-a or RAR-y proteins with that of Ki-67 antigen. These findings suggest that expression of RAR-a and RAR-y proteins in BCCs is not exclusively regulated by the proliferative activity of these tumor cells but is also influenced by different, unknown mechanisms. However, it should be noted that the usefulness of the Ki-67-defined antigen as a strict proliferation marker may be limited in BCCs by the well-known dysregulation of cell cycleassociated proteins in malignant tissues (Hall et al., 1990) . Other techniques, such as the detection of histone (H3) mRNA by in situ hybridization, may confirm our results showing that RAR expression in BCCs is not exclusively regulated by the proliferative activity of these tumor cells.
It can be speculated that upregulation of RAR-a protein is a mechanism involved in the pathogenesis or growth characteristics of BCCs. Our findings demonstrate that BCCs are potential targets of topical or systemic treatment with retinoic acid analogues that bind to RAR-a or RAR-y proteins and regulate gene transcription. We can also speculate that RAR-aor RAR-y-selective me-tabolites of retinoic acid may be interesting candidates for oral treatment or chemoprevention of BCCs that may evoke fewer side effects compared to all-trans retinoic acid.
Loss of RAR-P expression has been associated with acquisition of the malignant phenotype in many tissues and it has been suggested that RAR-P acts as a suppressor gene of tumorigenesis (Houle et al., 1993) . Therefore, it would be interesting to analyze whether expression of RAR-P can be induced by retinoic acid metabolites, as shown for many malignant and benign tissues in vivo and in vitro. This may be one reason for the therapeutic effectiveness of retinoic acid metabolites in the treatment or chemoprevention of BCCs.
